This Consolidated Litigation Involves Farxiga And Xigduo XR; Side Effects Include Diabetic Ketoacidosis And Kidney Damage
By means of this post, we are updating our March 8, 2017 article, "Pending Motion Requests Multidistrict Litigation (MDL) For Farxiga And Xigduo XR Lawsuits Filed In Federal Court".
On April 6, 2017 the United States Judicial Panel On Multidistrict Litigation (JPML) issued this document, "IN RE: FARXIGA (DAPAGLIFLOZIN) PRODUCTS LIABILITY LITIGATION TRANSFER ORDER -- MDL No. 2776", from which we get the following information:
The eighteen actions involve allegations that ingestion of the drug Farxiga may cause a variety of injuries, including diabetic ketoacidosis and kidney damage, and that defendants Bristol-Myers Squibb Co., AstraZeneca Pharmaceuticals LP, AstraZeneca LP, AstraZeneca PLC, and AstraZeneca AB (collectively, Bristol-Myers/AstraZeneca), which developed, manufactured, and marketed the drugs, failed to adequately test the drugs and warn of their risks. Farxiga and its sister drug Xigduo XR belong to a class of diabetes drugs known as Sodium Glucose Cotransporter 2 (SGLT2) inhibitors. Other SLGT2 inhibitors include Invokana (canagliflozin) and Jardiance (empagliflozin)....
On the basis of the papers filed and the hearing session held, we find that these actions involve common questions of fact, and that centralization of these cases will serve the convenience of the parties and witnesses and promote the just and efficient conduct of this litigation. The actions share factual questions arising from allegations that taking Farxiga or Xigduo XR may result in patients suffering kidney-related injuries, such as diabetic ketoacidosis and kidney damage. The actions thus implicate numerous common issues concerning the development, manufacture, testing, regulatory history, promotion, and labeling of the drugs.
The JPML went on to assign this new Farxiga MDL to Judge Lorna G. Schofield, who will preside over this consolidated litigation in the Southern District of New York federal court.
Strictly Confidential, No Obligation.
The FDA is investigating a connection between Farxiga and Xigduo XR -- as well as Invokana, Invokamet, Jardiance, Glyxambi, Synjardy, and Qtern -- with the following medical complications as drug side effects:
- Diabetic Ketoacidosis (DKA)
- Acute Kidney Injury
- Kidney Failure / Renal Failure
- Kidney Damage
- Pyelonephritis (kidney infection)
- Urosepsis (blood infection)
- Urinary Tract Infection (UTI)
- Heart Attacks / Myocardial Infarctions (MI)
- Ischemic Stroke / Cerebral Vascular Accident (CVA)
- Deep Vein Thrombosis (DVT)
- Pulmonary Embolism (PE)
- Heart Failure
- Leg Amputation
- Foot or Toe(s) Amputation
All of these diabetes drugs are Sodium-Glucose Co-Transporter-2 (SGLT2) Inhibitors, a new class of diabetes medicines.
We will continue to monitor legal and drug safety developments regarding Farxiga, Xigduo XR, and the several other SLGT2 inhibitor diabetes drugs.
DrugInjuryLaw.com: Medical & Legal Information About Drug Side Effects (All website content by attorney Tom Lamb)
Drug Injury Case Evaluation - Free. Confidential. No Obligation. (Case review done by attorney Tom Lamb)